The antibacterial-corticosteroid combination: What is its role in atopic dermatitis?

American Journal of Clinical Dermatology

Volumn 1, Issue 4, 2000, Pages 211-215

  Williams, Richard E A ^a  

^a GLAN CLWYD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CORTICOSTEROID;

ATOPIC DERMATITIS; HUMAN; MICROBIOLOGY; REVIEW; STAPHYLOCOCCUS INFECTION;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; DERMATITIS, ATOPIC; HUMANS; STAPHYLOCOCCAL INFECTIONS;

EID: 0034231645     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200001040-00002     Document Type: Article

References (32)

1. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1974; 90: 525-30
2. Williams REA, Gibson AG, Aitchison TC, et al. Assessment of a contact-plate sampling technique and subsequent quantitative bacterial studies in atopic dermatitis. Br J Dermatol 1990; 123: 493-501
3. Bibel DJ, Aly R, Shinefield HR, et al. The Staphylococcus aureus receptor for fibronectin. J Invest Dermatol 1983; 80: 494-6
4. Hay RJ, Adriaans BM. Bacterial infections. In: Champion RH, Burton JL, Burns DA, et al., editors. Rook/Wilkinson/Ebling textbook of dermatology. Oxford: Blackwell Science, 1998: 1097-179
5. Veien NK. Antibiotics in bacterial skin infections. Br J Dermatol 1998; 139 Suppl. 53: 30-6
6. White MI, Noble WC. The cutaneous reaction to staphylococcal protein A in patients with atopic dermatitis or psoriasis. Br J Dermatol 1985; 113: 179-83
7. McFadden JP, Noble WC, Camp RDR. Superantigenic exotoxin-secreting potential of staphylococci isolated from atopic eczematous skin. Br J Dermatol 1993; 128: 631-2
8. Jappe U, Heuck D, Witte W, et al. Superantigen production by Staphylococcus aureus in atopic dermatitis: no more than a coincidence? [letter]. J Invest Dermatol 1998 May; 110 (5): 844-6
9. Zollner TM, Kaufmann R. Superantigens in T cell mediated skin diseases - more than a coincidence [letter; comment]. J Invest Dermatol 1999 Jan; 112 (1): 118-9
10. Wachs GN, Maibach HI. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginised atopic dermatitis. Br J Dermatol 1976; 95: 323-8
11. Leyden JJ, Kligman AM. The case for steroid-antibiotic combinations. Br J Dermatol 1977; 96: 179-87
12. Lever R, Hadley K, Downey D, et al. Staphylococcal colonisation in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988; 119: 189-98
13. Ramsay CA, Savoie JM, Gilbert M. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. J Eur Acad Dermatol Venereol 1996; 7 Suppl. 1: S15-22
14. Hjorth N, Schmidt H, Thomasen K. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica 1985; 4: 126-31
15. Hill VA, Wong E, Corbett MF, et al. Comparative efficacy of betamethasone/ clioquinol (Betnovate-C) cream and betamethasone/fusidic acid (Fucibet) cream in the treatment of infected hand eczema. J Dermatol Treatment 1998; 9: 15-9
16. Poyner TF, Dass BK. Comparative efficacy and tolerability of fusidic acid/hydrocortisone cream (Fucidin H cream) and miconazole/hydrocortisone cream (Daktacort cream) in infected eczema. J Eur Acad Dermatol Venereol 1996; 7 Suppl. 1: S23-30
17. Meenan FOC. A double-blind comparative study to compare the efficacy of Locoid C with Tri-Adcortyl in children with infected eczema. Br J Clin Pract 1988; 42: 200-2
18. Jaffe GV, Grimshaw JJ. A clinical trial of hydrocortisone/potassium hydroxyquinolone sulphate (Quinocort) in the treatment of infected eczema and impetigo in general practice. Pharmatherapeutica 1986; 4: 628-36
19. Noble WC. Skin bacteriology and the role of Staphylococcus aureus in infection. Br J Dermatol 1998; 139 Suppl. 53: 9-12
20. Ewing CI, Ashcroft C, Gibbs ACC, et al. Flucloxacillin in the treatment of atopic dermatitis. Br J Dermatol 1998; 138: 1022-9
21. Charman C. Clinical evidence: atopic eczema. BMJ 1999; 318: 1600-4
22. White MI, Noble WC. Consequences of colonisation and infection by Staphylococcus aureus in atopic dermatitis. Clin Exp Dermatol 1986; 11: 34-40
23. Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 1992; 27: 29-34
24. Stadler JF, Fleury M, Sourisse M, et al. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol 1994; 131: 536-40
25. Slack RCB. Topical use of antimicrobial agents. In: Greenwood D, editor. Antimicrobial chemotherapy. Oxford: Oxford University Press, 1995; 387-94
26. Jackson D, Tasker TCG, Sutherland R, et al. Clinical pharmacology of Bactroban: pharmacokinetics, tolerance and efficacy studies. Curr Clin Pract 1985; 16: 54-67
27. Wilkinson JD, Shaw S. Contact dermatitis: allergic. In: Champion RH, Burton JL, Burns DA, et al., editors. Rook/Wilkinson/Ebling textbook of dermatology. Oxford: Blackwell Science, 1998: 733-819
28. Wakelin SH, Shaw S, Marren S, et al. Allergic contact dermatitis to newer topical anti-staphylococcal agents [abstract]. Br J Dermatol 1996; 135 Suppl. 47: 17
29. Smith RJ, Alder VG, Warin RP. Pyogenic cocci in infantile eczema throughout one year. BMJ 1975; 3: 199-201
30. Simpson-Dent SL, Hunt SJ, Hardman C, et al. Rates of fusidic acid resistance in paediatric dermatology patients - a 6-year study. Br J Dermatol 2000; 143 Suppl. 57: 127
31. Ravenscroft JC, Layton A, Murtagh M, et al. Study to assess the effect of short-term topical fusidic acid resistant (FusR) S. aureus in eczema patients. Br J Dermatol 2000; 143 Suppl. 57: 68-9
32. Chu T. Audit of new referrals with atopic dermatitis over a two month period. In: Hobbs FDR, editor. Managing Staphylococcus aureus in eczema. London: Royal Society of Medicine Press, 1999 (Round table Series 61): 7-14